Showing results (301-310 of 324) with videos related to
Sort By:
Pageof 33
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Lung Cancer (Amsterdam, Netherlands)|April 22, 2008
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapyReury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, et al.The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.Pageof 33